Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

4.19

Mkt cap

13M

Volume

25K

High

4.19

P/E Ratio

-0.09

52-wk high

152.40

Low

4.01

Div yield

N/A

52-wk low

1.80

Maxim Group analyst Naz Rahman has downgraded Cingulate (NASDAQ:CING) from Buy to Hold, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:37 pm

Quanex Building Products Corporation (NYSE:NX) shares dropped by 10.7% to $30.95 after reporting Q4 financial results. Other stocks experienced significant movements in Friday's mid-day session, with notable gainers including Getaround, Inc. (NYSE:GETR), Battalion Oil Corporation (NYSE:BATL), and Bruush Oral Care Inc. (NASDAQ:BRSH), among others. Losers included Chanson International Holding (NASDAQ:CHSN) and Inno Holdings Inc. (NASDAQ:INHD), with significant drops after recent gains or IPO pricing.

Portfolio Pulse from Avi Kapoor

December 15, 2023 | 5:46 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals (VRPX) saw a 57.8% increase, while Verrica Pharmaceuticals (VRCA) rose by 51.06%. ASLAN Pharma (ASLN), Biophytis (BPTS), Context Therapeutics (CNTX), and Immix Biopharma (IMMX) also saw gains. Conversely, Aadi Bioscience (AADI), Aileron Therapeutics (ALRN), Cingulate (CING), Vapotherm (VAPO), SenesTech (SNES), and IN8bio (INAB) experienced declines, with AADI dropping 56.5%.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:31 pm

Cingulate's CFO Louis G. Van Horn retired effective immediately on Dec 13, as per an SEC filing. Shane Schaffer will serve as the interim Principal Financial Officer until a new CFO is appointed.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:00 pm

Cingulate Inc. shares have resumed trading, indicating a potential change in the company's status or recent news affecting its stock.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:01 pm

Cingulate Inc. announced a 1-for-20 reverse stock split effective November 30, 2023. The split will adjust outstanding shares and securities but won't change shareholder equity percentages, except for rounding fractional shares to whole. The Board had the discretion to choose the ratio, which will not alter the par value or authorized shares. The CUSIP number for the Common Stock will change to 17248W204.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:26 pm

Cingulate reported an improvement in its Q3 2023 earnings per share (EPS) to $(0.30) from $(0.36) year-over-year (YoY).

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:36 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Tivic Health Systems (TIVC) saw a 116.8% increase, while SenesTech (SNES) rose by 65.78%. ZyVersa Therapeutics (ZVSA) and Cingulate (CING) also experienced gains. On the downside, TC BioPharm (TCBP) dropped by 89.2%, Aclaris Therapeutics (ACRS) fell by 85.6%, and Verve Therapeutics (VERV) declined by 31.53%. Other stocks such as TRACON Pharma (TCON), Monopar Therapeutics (MNPR), and Singular Genomics Systems (OMIC) also saw decreases. Earnings reports seem to be a driving factor for many of these movements.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 1:06 pm

In Monday's after-market session, several healthcare stocks saw significant movement. Senti Biosciences, TransMedics Gr, Augmedix, Lucy Scientific Discovery, NanoString Technologies, and ThermoGenesis Holdings saw increases, with Senti Biosciences leading with a 187.7% increase. On the other hand, Coherus BioSciences, Aura Biosciences, MSP Recovery, NeuroPace, Tactile Systems Tech, and Cingulate saw decreases, with Coherus BioSciences experiencing the largest drop of 23.7%.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:31 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. Bellerophon Therapeutics, Cingulate, Rain Oncology, Artelo Biosciences, Processa Pharma, and Eiger BioPharmaceuticals saw gains, while Eloxx Pharmaceuticals, TRACON Pharma, Universe Pharmaceuticals, Purple Biotech, RVL Pharmaceuticals, and OpGen experienced losses.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.